source
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
- Novo signs $1.4 billion deal with Orbis Medicines to develop oral macrocycle cardiometabolic drugsNovo, which recently rebranded from Novo Nordisk, announced a partnership with Copenhagen‑based Orbis Medicines. The agreement could provide up to $1.4 billion in upfront payments and milestone pay…